Cholestagel: Phase III

Preliminary data from a 100-patient European Phase III trial showed that a 3.8 g once daily dose of Cholestagel had similar efficacy to two 1.9 g doses in the study's primary efficacy variable of change in LDL cholesterol. The change in LDL cholesterol in the study was 15-18 percent for the two dosing regimens versus placebo (p<0.0001 for both regimens). Patients were treated for six weeks following a six week diet period. ...